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ABSTRACT
Aims ToreportprogressamongPartiestotheWorldHealthOrganization(WHO)FrameworkConventiononTobacco
Control (FCTC) in developing tobacco dependence treatment systems in accordance with FCTC Article 14 and the
Article 14 guidelines recommendations. Design Cross-sectional study. Setting Electronic survey from December
2011 to August 2012. Participants One hundred and sixty-three of the 174 Parties to the FCTC at the time of our
survey. Measurements The 51-item questionnaire contained 21 items speciﬁcally on treatment systems. Questions
covered the availability of basic treatment infrastructure and national cessation support systems. Findings We
received responses from 121 (73%) of the 166 countries surveyed. Fewer than half of the countries had national
treatmentguidelines(n = 53,44%),agovernmentofﬁcialresponsiblefortobaccodependencetreatment(n = 49,41%),
an ofﬁcial national treatment strategy (n = 53, 44%) or provided tobacco cessation support for health workers (n = 55,
46%). More than half encouraged brief advice in existing health care services (n = 68, 56%), while only 44 (36%)
had quitlines and only 20 (17%) had a network of treatment support covering the whole country. Low- and middle-
income countries had less tobacco dependence treatment provision than high-income countries. Conclusion Most
countries, especially low- and middle-income countries, have not yet implemented the recommendations of
FCTC Article 14 or the FCTC Article 14 guidelines.
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INTRODUCTION
Article 14 of the 2005 World Health Organization
(WHO) Framework Convention on Tobacco Control
(FCTC) [1] requires Parties to take effective measures to
promote cessation of tobacco use and adequate treat-
ment for tobacco dependence. In November 2010 the
fourth Conference of the Parties to the FCTC adopted
guidelinesfortheimplementationof Article14[2].These
guidelines amount to ofﬁcial policy on tobacco depend-
ence treatment for Parties to the Convention and, inter
alia, outline the basic infrastructure needed to support
tobacco cessation and key components of a national
system to help tobacco users quit. Tobacco dependence
treatment is deﬁned by the Article 14 guidelines as: ‘The
provisionof behaviouralsupportormedications,orboth,
to tobacco users, to help them stop their tobacco use’ [2].
The basic infrastructure elements to support tobacco
cessation include the following [2]:
• A focal point or national coordinating mechanism
• A national cessation strategy
• National treatment guidelines
• Programmes to encourage health care workers who
use tobacco to stop and support to help them do so
• National training standards
• The use, as far as possible, of existing infrastructure
including but not limited to HIV/AIDS, tuberculosis
and related services
• Mandatory reporting of tobacco use in all medical
notes
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tion support
The key components of a national cessation support
system include [2]:
• Mass communication and education programmes to
encourage cessation
• Brief advice integrated into all health care systems
• Quitlines
• Access to affordable medications
• Specialized tobacco dependence treatment services
The Article 14 guidelines suggest that Parties develop
cessation support in a stepwise order: ﬁrst establish basic
infrastructure elements; then address the issue in health-
care workers; integrate brief advice into existing health-
care systems; and ﬁnally develop treatment support,
including quitlines and specialist services. Finally, the
guidelines state that treatment should be widely avail-
able, accessible and affordable and that cessation and
treatment strategies should be monitored.
In this paper we report the results of a survey whose
objective was to review the state of tobacco dependence
treatment systems and national treatment guidelines in
Parties to the FCTC, in order to gauge progress in imple-
menting Article 14 and its guidelines. The survey builds
on a previous survey, the results of which were published
in 2009 [3,4]. We report here the treatment system
results; the results on national treatment guidelines are
reported in a separate paper [5].
METHODS
There were 174 Parties to the FCTC, including the Euro-
pean Union (EU), in addition to its member countries,
at the time our survey began in December 2011. We
excluded the EU, and we were unable to ﬁnd contacts in
10 Parties (two high-income, three upper-middle-
income, two lower-middle-income and three low-income
countries), thus 163 Parties were surveyed. The United
Kingdom, which is a Party, consists of four countries,
England, Northern Ireland, Scotland and Wales, each
with separate health care systems and treatment guide-
lines, so we surveyed all four individually. Our ﬁnal
sample therefore consisted of 163 FCTC Parties or 166
countries. Our sample of contacts—a mixture of treat-
ment specialists, FCA members and government
ofﬁcials—was identiﬁed from those used in the previous
survey [3,4], our own contacts and recommendations
from a range of organizations. We endeavoured to
identify people who were likely to be knowledgeable
about tobacco cessation and treatment provision in their
countries.
We e-mailed 166 people starting in December 2011,
inviting them to participate in our survey by either click-
ing on a link to the online survey or by completing an
attached Word questionnaire (offered in English, French
and Spanish). We followed-up non-responders with
reminder e-mails in January, February, April and May
2012.
The questionnaire contained 51 items, 21 speciﬁcally
ontreatment,andisavailableintheonlineversionof this
paper. Responses to the question on availability and
licensing of medications proved difﬁcult to interpret,
partlybecauseof itsconstruction.Thus,wealsoe-mailed
manufacturers of the four principal cessation medica-
tions and asked them to provide data on availability of
their medications internationally. These data were used
as the base to check respondents’ awareness of availabil-
ity and perceived affordability.
Countries were categorized by WHO region [6] and
WorldBankincomelevelinAugust2012,basedonGross
NationalIncome(GNI)percapitain2011.Thecategories
are low-income ($1025 or less), lower-middle-income
($1026–4035), upper-middle-income ($4036–12 475)
andhigh-income($12 476ormore)[7].Wereportedthe
distribution of our respondents by WHO region and
World Bank income category and present the main ﬁnd-
ings broken down by income category.
RESULTS
We received responses from 121 of the 166 countries
surveyed, a response rate of 73%. Our United Arab Emir-
ates contact completed the survey only for Abu Dhabi.
The highest and lowest response rates by region were
83% in Europe and South-East Asia, and 65% in the
Western Paciﬁc region (Fig. 1). By World Bank income
level, the highest response rate was 78% in high-income
countries, and the lowest was 67% in lower-middle-
income countries.
Basic infrastructure elements
According to respondents, fewer than half of countries
had an ofﬁcial national treatment strategy (44%), a gov-
ernment ofﬁcial responsible for tobacco dependence
treatment (41%) or national tobacco treatment guide-
lines(44%).Onlyone-ﬁfthof countrieshadaclearlyiden-
tiﬁed treatment budget, and 22% did not monitor the use
of treatment services (Table 1); just under half offered
tobacco cessation assistance to health workers (46%).
Twenty-two per cent of countries mandated the record-
ing of patients’ tobacco use in medical notes. Just over a
quarter of countries had national training standards.
National cessation support system
Just over half of countries ran anti-tobacco mass media
campaigns (54%) or encouraged the provision of brief
advice in existing services (56%) (Table 2).
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Respondents in 36% of countries (44 of 121) reported
havingquitlines.Themajorityof thesewerefreetocallers
and had people (rather than machines) answering calls
mostof thetime.Morethanhalf offeredmultiplesessions
with call-back offering support, while 86% referred
callers to local specialist treatment services and 80%
offered information on tobacco cessation medications.
Tobacco cessation medications were offered to callers by
one-ﬁfth of quitlines.
Specialist treatment facilities
Respondentsinone-thirdof countriesreportedhavingno
specialized treatment facilities at all; just over half had
treatment support in selected areas, while 17% had a
network of treatment support which covered the whole
country (Table 2).
Access to help
Respondents in almost one-third (30%) of countries indi-
cated that tobacco users could obtain help easily in a
general/family practice setting, while 17% said the same
for pharmacists, 7% for dentists, 18% for hospitals and
23% from the internet (Fig. 2).
Access to medications
Based on manufacturer data, varenicline and nico-
tine replacement therapy (NRT) were the most widely
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Figure 1 Survey response rates by region and World Bank income level of respondent countries
Table 1 Basic infrastructure elements by World Bank income level of respondent countries.
Question
%Yes (n)
All
(n = 121)
High
(n = 36)
UM
(n = 36)
LM
(n = 30)
Low
(n = 19)
Does your country have an ofﬁcial national treatment strategy? 44 (53) 58 (21) 47 (17) 33 (10) 26 (5)
Is there an ofﬁcially identiﬁed person who is responsible for
tobacco dependence treatment?
41 (49) 47 (17) 44 (16) 40 (12) 21 (4)
Does your country have national guidelines for the treatment of
tobacco dependence?
44 (53) 75 (27) 42 (15) 30 (9) 11 (2)
Have a clearly identiﬁed budget for treatment? 20 (24) 36 (13) 17 (6) 17 (5) 0 (0)
Does your country monitor the use of treatment services? 22 (27) 42 (15) 25 (9) 10 (3) 0 (0)
Does your country offer help to health care workers to stop
using tobacco?
46 (55) 56 (20) 47 (17) 40 (12) 32 (6)
Does your country have mandatory recording of patients’
tobacco use status in medical notes?
22 (26) 28 (10) 25 (9) 13 (4) 16 (3)
Does your country have national training standards? 26 (31) 42 (15) 25 (9) 13 (4) 16 (3)
LM = lower-middle-income; UM = upper-middle-income. Missing data ranged from zero to 1%.
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Question
%Yes (n)
All
(n = 121)
High
(n = 36)
UM
(n = 36)
LM
(n = 30)
Low
(n = 19)
Does your country run mass media campaigns promoting
cessation?
54 (65) 69 (25) 50 (18) 43 (13) 47 (9)
Does your country promote/encourage brief advice in existing
services?
56 (68) 56 (20) 50 (18) 60 (18) 63 (12)
Does your country have a telephone quitline? 36 (44) 75 (27) 28 (10) 20 (6) 5 (1)
• Is it free to callers calling in? 73 (32) 74 (20) 60 (6) 83 (5) 100 (1)
• Does it have people answering always or almost always? 80 (35) 85 (23) 60 (6) 83 (5) 100 (1)
• Does it offer multiple sessions with counsellors calling back
offering ongoing support?
56 (24) 70 (19) 30 (3) 33 (2) 0 (0)
• Does it refer to local specialist treatment services? 86 (38) 85 (23) 100 (10) 67 (4) 100 (1)
• Does it offer information about tobacco cessation
medications?
80 (35) 85 (23) 70 (7) 67 (4) 100 (1)
• Does it offer tobacco cessation medications to callers? 21 (9) 22 (6) 10 (1) 33 (2) 0 (0)
Countries with nation wide specialized tobacco dependence
treatment facilities
17 (20) 36 (13) 19 (7) 0 (0) 0 (0)
Countries with treatment facilities but only in selected areas 51 (62) 50 (18) 56 (20) 57 (17) 37 (7)
Countries with no specialized treatment at all 32 (39) 14 (5) 25 (9) 43 (13) 63 (12)
LM = lower-middle-income; UM = upper-middle-income. Missing data ranged from zero to 1%. The base for the quitline questions (in bullet points)
for all countries was the 44 countries with quitlines and for the respective income categories was the number of countries having quitlines in each
category.
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Figure 2 Can tobacco users obtain help easily to stop in the following settings? (Overall responses and responses by World Bank
income level of respondent countries).The bars show the proportion answering ‘Yes, easily’ (Yes); the other responses were ‘Not easily’
and ‘No’
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the respondent countries (Table 3). Respondents’ aware-
ness that medications were available ranged from 67%
with cytisine to 100% with bupropion.
We asked respondents if a medication was ‘easily
affordable to most tobacco users’. In countries whose
respondents knew that the medication was available,
cytisine was reported to be easily affordable in all coun-
tries, while varenicline was said to be the least easily
affordable (Table 4).
Relationship between treatment provision and Parties’
World Bank income level
In almost all cases, low- and middle-income countries
had fewer basic infrastructure elements than high-
income countries (Table 1). Fifty-eight per cent of high-
income countries had an ofﬁcial national treatment
strategy, while just over a quarter of low-income coun-
triesdid.Justunderhalf of high-incomecountrieshadan
ofﬁcial responsible for treatment compared to only a ﬁfth
of low-income countries.Three-quarters of high-income
countries had treatment guidelines as opposed to just
11% of low-income countries, and just over a third of
high-income countries had a clearly identiﬁed treatment
budget compared with no low-income countries.
Asimilarpicturewasobservedwithmostcomponents
of national cessation support systems. More than two-
thirds of high-income countries ran mass media cam-
paigns promoting cessation, compared with fewer than
half of low-income countries, and 75% of high-income
countries provided quitlines compared with 5% of low-
income countries. Finally, 36% of high-income countries
provided specialist treatment facilities covering the whole
country, whereas no low- or lower-middle-income
countrydid,andonly14%of high-incomecountriespro-
vided no specialist treatment facilities at all, compared
with 63% of low-income countries (Table 2). Conversely,
63% of low-income countries and 60% of lower-middle-
income countries encouraged the provision of brief
advice in existing services compared to 56% of high-
income countries.
Access to help was rated as being easily available in
general practice, pharmacies, hospitals and the internet
in high-income countries, but not in any of the other
World Bank income categories (Fig. 2).
The availability of NRT, bupropion and varenicline
was lower in lower-income countries (Table 3). No
low-income countries at all had NRT or bupropion,
nor was bupropion available in any lower-middle-
income countries. Cytisine was most widely available
in upper-middle-income countries (17%), followed by
Table 3 Availability of medications by World Bank income level of respondent countries.
Medication
Availability according to manufacturer
% (n)
Respondents’ awareness of medication
availability % (n/base)
All
(n = 121)
High
(n = 36)
UM
(n = 36)
LM
(n = 30)
Low
(n = 19) All
NRT 51 (62) 97 (35) 61 (22) 17 (5) 0 (0) 92 (57/62)
Bupropion 17 (20) 42 (15) 14 (5) 0 (0) 0 (0) 100 (20/20)
Varenicline 52 (63) 83 (30) 58 (21) 33 (10) 11 (2) 86 (54/63)
Cytisine 10 (12) 3 (1) 17 (6) 13 (4) 5 (1) 67 (8/12)
LM = lower-middle-income; NRT = nicotine replacement therapy; UM = upper-middle-income. The bases used in the ﬁnal column were the ‘n’ values
given for the respective medications in the second column.
Table 4 Affordability of medications by World Bank income level of respondent countries.
Medication
Affordability of medications known to be available
% (n/base)
All High UM LM Low
NRT 81 (46/57) 94 (32/34) 60 (12/20) 67 (2/3) –
Bupropion 70 (14/20) 80 (12/15) 40 (2/5) – –
Varenicline 48 (26/54) 64 (18/28) 32 (6/19) 29 (2/7) 0 (0)
Cytisine 100 (8/8) 100 (1/1) 100 (4/4) 100 (2/2) 100 (1/1)
LM = lower-middle-income; NRT = nicotine replacement therapy; UM = upper-middle-income.The bases used in the second column were the ‘n’ values
for respondents’ awareness of availability of the respective medications given in Table 3.
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countries (5%), and was least available in high-income
countries(3%).Theperceivedaffordabilityof medications
showed a similar pattern; it decreased steadily from high-
to low-income countries except for cytisine, which was
considered affordable in all countries where it was avail-
able (Table 4).
Relationship between treatment provision and Parties’ WHO
region
No consistent pattern was observed in treatment pro-
vision by WHO region except for Africa, which was
generally lower than other regions.
DISCUSSION
Only a minority of countries had in place the key infra-
structure needed to offer cessation support to tobacco
users. A small majority reported promoting cessation
through mass media campaigns and encouraging brief
advice in existing services. However, cessation help was
rated as easily accessible in very few settings indeed, and
even then only in high-income countries. A third of
countries had no specialized treatment services at all.
Availability of medications was limited, and they were
frequently perceived to be unaffordable. In general, the
provision of cessation support was much lower in lower-
income countries.
This study has both strengths and limitations. A key
limitation of this study is that it relied upon the knowl-
edge of our contacts and, for the most part, their
responses could not be validated, although we made a
considerable effort to identify contacts as knowledgeable
as possible about tobacco cessation. Where responses
were unclear we corresponded with respondents to
ensure that the questions had not been misinterpreted
and to clarify their responses. With some questions we
acknowledge a degree of subjectivity in interpretation of
their meaning, but there was a trade-off between attain-
ing as large a sample as possible and keeping the ques-
tionnaire to a manageable size. With one question, on
medications, we had difﬁculty interpreting the responses
because of the way it was constructed, so we supple-
mented this with manufacturers’ data.
In addition, the proportion of countries running mass
media campaigns was higher than we expected; respond-
ents may have included the use of unpaid media and
media advocacy as well as paid mass media campaigns
when responding to this question.The principal strength
of this survey is that it is, to our knowledge, the most
extensive, detailed survey of tobacco cessation support
conducted to date, with responses from 68% of FCTC
Parties.
Basic cessation infrastructure
TheFCTCArticle14guidelines(theFCTCguidelines)rec-
ommend a stepwise approach to promoting tobacco ces-
sation and developing support, and they also recommend
prioritizing approaches to providing support that are
broad-reachandlow-cost[2].Ourresultsshowthatmost
countries have not yet put into place the most basic
infrastructure for promoting cessation and treatment,
including an ofﬁcial responsible for cessation, an ofﬁcial
national strategy and national treatment guidelines, this
last a treaty obligation.
The FCTC guidelines also stress that addressing
tobacco use in health care workers is a priority. Health-
care workers are health role models [8,9], tobacco use in
this group undermines anti-tobacco public health mes-
sages [9], and makes health care workers less likely to
encourage their patients to quit [8,9]. Rates of tobacco
use by health professionals are as high as 40% in some
countries[10,11],yetfewerthanhalf of countriesoffered
support to this group.
Routine recording of patients’ tobacco use in medical
notes is essential if health professionals are to identify
and advise all tobacco users. The FCTC guidelines stress
that all countries should implement this measure; fewer
than a quarter have done so.
Few countries had national training standards or a
system for monitoring service provision. This may be
partly because of cost, and is an area where high-income
countries might well be able to support lower income
countries, as is encouraged by the FCTC itself.
National cessation support system
More than half of countries ran mass media campaigns
promoting cessation. Such campaigns are crucial to
combat the effects of tobacco industry marketing [8] as
they inﬂuence attitudes to tobacco use, discourage the
initiation of tobacco use, motivate quit attempts, gener-
ate demand for cessation support and inform people as to
what support is available [12].
Brief advice
As noted above, the FCTC guidelines recommend inte-
grating brief advice into the health care system as a high
priority [2], and state that all countries should be doing
this. The 2009 MPOWER report [13] recommends that
all countries should provide brief advice, quitlines and
access to low-cost medications. Brief advice is one of the
most cost-effective disease prevention interventions [14],
and its incorporation into health care systems such as
primary care would achieve good population coverage at
relatively low cost. Repeated exposure to cessation mes-
sages in health care settings has also been shown to
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Only just over half of countries surveyed promoted brief
advice in existing services; we believe this intervention
should be prioritized urgently. Delivery of brief advice is
likely to be linked to the recording of tobacco use in
patients’ notes. If tobacco use is recorded and updated
regularly in patient notes this will act as a prompt to offer
cessation advice on a regular basis.
Quitlines
Just over a third of countries had quitlines. Overall, the
majority were free and were answered by people most of
the time, but only just over half offered multiple sessions,
with counsellors calling back to offer ongoing support.
Although quitlines are much cheaper than face-to-face
specialist treatment, these results illustrate the greater
provision of cessation support in higher-income coun-
tries, and possibly suggest that for low-income countries
even quitlines may be perceived to be relatively expensive
[16]. Even lower-cost options such as the use of text mes-
saging (to support tobacco users trying to quit) deserve
study [17].
Specialist treatment facilities
Specialized tobacco treatment services were available
widely in very few countries, and a third (63% in low-
income countries) had no treatment services at all. The
relatively high cost of establishing specialist services is
almost certainly a deterrent to many countries, which is
whytheFCTCguidelinesurgecountriessostronglynotto
develop such services until lower-cost broader-reach
interventions have been established. A number of
middle-income countries [18] have established a system
of specializedtreatmentclinicswhichwouldbeextremely
difﬁcult to expand even if they could afford to do so. For a
countrywithverylimitedresourcestostartwith,special-
ist services are unlikely to be a cost-effective use of these
limited resources.
Access to help
In the vast majority of countries, very few tobacco users
could obtain help easily to stop tobacco use in any set-
tings. Help was available most readily in general/family
practice, but even in this setting tobacco users could
obtain help easily in only 30% of countries. No other
setting reached 25%. Clearly, to expand access to cessa-
tionhelpquickly,countriesshouldfollowtheFCTCguide-
lines’recommendationstofocusonlow-costbroad-reach
interventions and on using existing infrastructure, such
as primary care, to the maximum extent possible. Access
tosupportontheinternetwasalsolow.Givenitspotential
cost-effectiveness this approach merits more research.
Access to medications
Cessation attempts using medications are more success-
ful than those made without medications [19–24], thus
medications have an important role to play in assisting
cessation. However, they were not available in all coun-
tries and in many, especially lower-income countries,
were perceived as being unaffordable. Unfortunately,
most countries’ health care systems do not cover the cost
of tobacco cessation medications and in some countries
even NRT, one of the less expensive medications, is far
more expensive than cigarettes [25,26]. In our survey,
respondents in 70% or more of countries rated NRT and
bupropionaseasilyaffordable,butvareniclinewasjudged
to be affordable in fewer than half the countries in which
it is available.The FCTC guidelines urge countries to look
at ways of reducing the cost of medications, including by
bulk-buying, for example. Cytisine was rated as being
‘easily affordable to most tobacco users’ in all eight coun-
tries where it was available. One was high-income, four
were upper-middle-income countries, two were lower-
middle-income countries and one was low-income. The
fact that a course of cytisine is reported to cost US$15 or
less [27,28] suggests that more widespread licensing of
cytisine could make it affordable to millions of tobacco
users currently unable to afford medications.
Relationship between treatment provision and Parties’
World Bank income level
Perhaps not surprisingly, almost all aspects of cessation
provision were more common in higher-income coun-
tries, with the high availability of help from the internet
probably reﬂecting better internet access in these coun-
tries. A comprehensive specialist treatment service cover-
ing the whole country, such as that established in
England in 1999, can be expensive. The English services
weresetupwithaninitialbudgetof $83million[29].We
know informally that many countries are concerned by
the perceived cost of cessation support, and it is because
of this that the FCTC guidelines emphasize so strongly
startingwithaffordable,broad-reachapproaches,includ-
ing brief advice and quitlines. Our ﬁnding that the pro-
motion of brief advice was more common in lower- than
in higher-income countries might suggest that countries
are beginning to take this message on board.
Relationship between treatment provision and Parties’
WHO region
The only consistent ﬁnding in treatment provision by
WHO region was that provision in Africa was generally
lower than in other regions, probably as a result of
the predominance of low- and lower-middle-income
countries in the region.
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To our knowledge, this is the most extensive survey of
tobacco dependence treatment conducted to date, with
responses from more than two-thirds of FCTC Parties.
Overall, tobacco cessation support and treatment appear
to be a low priority for most Parties, especially lower-
income countries. The FCTC Article 14 guidelines
recommend that before establishing treatment services,
countries ﬁrst put into place measures proposed in other
Articles of the FCTC (especially Articles 6, 8, 11, 12 and
13) that are designed to promote cessation and likely to
create demand for cessation support. The Article 14
guidelines do, however, acknowledge the need for ﬂexibil-
ity, and recommend that brief advice should be imple-
mented in all countries as a priority.There remains much
room for improvement in the extent to which low-cost
broad-reach interventions can be implemented in low-
and middle-income countries, with an emphasis on
the stepwise approach advocated by the Article 14
guidelines.
Other areas requiring attention are establishing
national coordinating mechanisms, ofﬁcial national
strategies and help for health care workers to quit.
Finally, tobacco dependence treatment is highly cost-
effective, and therefore should be a higher priority in
higher-income countries.
Treatment provision is an integral part of wider
tobacco control measures being implemented by Parties,
as it indicates governments’ recognition that tobacco use
is addictive, and willingness to provide support to those
who genuinely need it. As stated in the FCTC Article 14
guidelines, providing these services increases accept-
ability of and social support for other tobacco control
policies [2].
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